Moderna (NASDAQ:MRNA) Stock Rating Upgraded by Hsbc Global Res

Hsbc Global Res upgraded shares of Moderna (NASDAQ:MRNA - Free Report) from a hold rating to a strong-buy rating in a research note released on Monday,Zacks.com reports.

Several other research analysts also recently weighed in on MRNA. Wolfe Research initiated coverage on Moderna in a research note on Friday. They set an "underperform" rating and a $40.00 price target for the company. Bank of America reduced their target price on shares of Moderna from $130.00 to $110.00 and set a "neutral" rating for the company in a research note on Friday, September 13th. Deutsche Bank Aktiengesellschaft upgraded shares of Moderna from a "sell" rating to a "hold" rating and dropped their price target for the company from $85.00 to $80.00 in a research note on Wednesday, August 7th. Piper Sandler reiterated an "overweight" rating and issued a $69.00 price objective (down from $115.00) on shares of Moderna in a research note on Monday. Finally, The Goldman Sachs Group lowered their target price on shares of Moderna from $178.00 to $139.00 and set a "buy" rating on the stock in a report on Monday, September 16th. Three equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Moderna has an average rating of "Hold" and an average target price of $84.00.

Moderna Stock Performance

Shares of Moderna stock traded down $2.22 during trading hours on Monday, hitting $37.29. 9,113,315 shares of the company's stock traded hands, compared to its average volume of 4,770,895. The stock has a market capitalization of $14.35 billion, a price-to-earnings ratio of -6.59 and a beta of 1.69. Moderna has a 12-month low of $35.80 and a 12-month high of $170.47. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The company has a fifty day simple moving average of $57.82 and a 200-day simple moving average of $96.07.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. During the same quarter last year, the business posted ($1.39) EPS. Moderna's quarterly revenue was up 3.8% compared to the same quarter last year. Equities research analysts anticipate that Moderna will post -9.43 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO James M. Mock sold 715 shares of Moderna stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the transaction, the chief financial officer now owns 9,505 shares in the company, valued at $571,440.60. This trade represents a 7.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 2,930 shares of company stock worth $217,170 in the last quarter. 15.20% of the stock is owned by insiders.

Institutional Trading of Moderna

Several institutional investors have recently added to or reduced their stakes in the business. Teachers Retirement System of The State of Kentucky boosted its holdings in Moderna by 1.4% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 287,887 shares of the company's stock valued at $19,239,000 after acquiring an additional 3,978 shares during the period. Toronto Dominion Bank lifted its position in Moderna by 23.7% in the third quarter. Toronto Dominion Bank now owns 131,477 shares of the company's stock valued at $8,787,000 after purchasing an additional 25,177 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Moderna by 2.6% during the third quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company's stock valued at $470,670,000 after purchasing an additional 178,115 shares during the period. Groupama Asset Managment grew its holdings in shares of Moderna by 29.1% in the third quarter. Groupama Asset Managment now owns 21,838 shares of the company's stock worth $1,459,000 after purchasing an additional 4,920 shares during the last quarter. Finally, Nomura Asset Management Co. Ltd. raised its holdings in Moderna by 1.5% during the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 114,335 shares of the company's stock valued at $7,641,000 after buying an additional 1,635 shares during the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.